Click to read the Medicines Patent Pool (MPP)’s most recent brochure. The document explains how MPP works to increase access to treatments in low- and middle-income countries, and it also presents some key figures about MPP’s achievements from 2010 to date.

MPP_Greater Access Brochure

 
 

Introduction: Bridging the Gap in Medicine Access

Millions of people in low- and middle-income countries (LMICs) lack access to essential treatments for diseases such as HIV, hepatitis C, tuberculosis, cancer, and cardiovascular conditions. MPP works to improve availability through partnerships, licensing, and local production models.

 

Why Access Matters

  • 2.32 million deaths from preventable infectious diseases in 2022.
  • 70% of global cancer deaths occurred in LMICs.
  • Maternal mortality remains highest in Sub-Saharan Africa.
  • Half of LMIC populations lack consistent access to essential medicines.
  • Pandemic preparedness is hindered by unequal vaccine access.

 

Licensing for Public Health Technologies

MPP partners with patent holders and generic manufacturers to negotiate licences that allow for the development and distribution of affordable treatments. These non-exclusive licences promote competition and innovation while ensuring equitable access across 148 countries.

Key Benefits of the Licensing Model:

  • 🌍 Wide geographical reach: Licences cover a broad range of LMICs

  • 💊 Quality-assured medicines: Products meet global standards

  • 🔁 Flexible and adaptive: Designed to meet evolving public health priorities

  • 📄 Transparent agreements: All licences are publicly available

  • 🏥 Support for local production: Encourages sustainable manufacturing capacity

Driving Access to Health Technologies Through Innovation

MPP’s approach not only facilitates access to existing treatments, but also supports the development of new formulations and health technologies; including medicines for non-communicable diseases, maternal health, and pandemic response tools.

 

Real-World Impact

Through MPP’s licences:

  • 💉 43.56 billion doses have been supplied (2012–2023)

  • 💵 $3.9 billion in savings projected by 2030

  • ❤️ 170,000 lives projected to be saved by 2030

  • 👥 118 million patient-years of treatment delivered through generic partners

 

Impact So Far

  • 43.56 billion doses supplied since 2012
  • $1.9 billion saved (2012–2023) and $3.9 billion projected by 2030
  • 170,000 deaths averted projected by 2030
  • 56 generic partners across 14 countries
  • 22 patent holders engaged in voluntary licensing

Advancing Global Health Equity Through Access

By creating partnerships across 56 generic manufacturers and 22 patent holders, MPP helps bridge the gap in access to medicines and health technologies in LMICs. This scalable model promotes long-term sustainability and empowers local health systems.